Compare LNN & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNN | DRTS |
|---|---|---|
| Founded | 1954 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 1995 | 2021 |
| Metric | LNN | DRTS |
|---|---|---|
| Price | $116.17 | $14.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $113.00 | $8.67 |
| AVG Volume (30 Days) | 92.3K | ★ 483.3K |
| Earning Date | 04-02-2026 | 05-18-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | ★ 12.81 | N/A |
| EPS | ★ 4.22 | N/A |
| Revenue | ★ $676,368,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.74 | $699.98 |
| P/E Ratio | $27.52 | ★ N/A |
| Revenue Growth | ★ 11.41 | N/A |
| 52 Week Low | $97.27 | $3.14 |
| 52 Week High | $148.00 | $14.75 |
| Indicator | LNN | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 56.06 | 66.63 |
| Support Level | $116.15 | $6.59 |
| Resistance Level | $120.01 | N/A |
| Average True Range (ATR) | 3.16 | 0.68 |
| MACD | 0.25 | 0.09 |
| Stochastic Oscillator | 81.63 | 97.43 |
Lindsay Corp provides proprietary water management and road infrastructure products and services. It manufactures and distributes agricultural irrigation equipment through two segments: Irrigation and Infrastructure. The Irrigation segment makes center pivot, lateral move, and hose reel irrigation systems and parts. The Infrastructure segment produces barriers, crash cushions, road marking and safety equipment, and railroad signals. The majority of revenue is from the Irrigation segment. The company operates in the United States and international markets, with the majority of revenue coming from the United States.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.